Key Points
-
Coincident with the rise of obesity, NAFLD has become the most common cause of chronic liver injury in the industrialized world in both children and adults
-
The mainstay of treatment for both adult and paediatric NASH are diet and exercise resulting in weight loss
-
Medical treatment of NAFLD should be considered only for those patients with biopsy-proven NASH who have failed lifestyle intervention; current medical therapies lack long-term safety and efficacy data
-
Transitioning to adult care should begin in early adolescence and should be multifaceted
-
Paediatric providers should prepare patients to take an active role in their care, have an understanding of their disease, and should assess logistical and psychosocial challenges that might impair transition
-
Adult providers should be aware of the differences between paediatric and adult NAFLD to provide a smooth transition process that is integrated with the paediatric model
Abstract
NAFLD is the most common chronic liver disease in children and adults, with its prevalence closely associated with obesity and other features of the metabolic syndrome. As young adults with NAFLD transition from the paediatric care environment to adult services, establishing a coordinated model of transition to ensure ongoing and appropriate care is critical. Enabling a smooth transfer begins with an understanding of the key differences between paediatric and adult NAFLD as well as the psychosocial factors that affect older adolescents. This Review summarizes the literature on paediatric NAFLD from the past two decades with a focus on the differences in epidemiology, pathology, pathophysiology and treatment that are relevant to clinicians who transition paediatric patients to adult care. An integrated model, which employs a team of adult and paediatric providers who can address the psychosocial, cognitive and logistical challenges of transition, provides the best opportunity for a seamless and coordinated transfer to adult care.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ogden, C. L., Carroll, M. D., Kit, B. K. & Flegal, K. M. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA 311, 806–814 (2014).
Finkelstein, E. A., Trogdon, J. G., Cohen, J. W. & Dietz, W. Annual medical spending attributable to obesity: payer- and service-specific estimates. Health Aff. (Millwood) 28, w822–w831 (2009).
Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009).
Brunt, E. M. Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 7, 195–203 (2010).
Fraser, A., Longnecker, M. P. & Lawlor, D. A. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999–2004. Gastroenterology 133, 1814–1820 (2007).
Schwimmer, J. B. et al. Prevalence of fatty liver in children and adolescents. Pediatrics 118, 1388–1393 (2006).
Vernon, G., Baranova, A. & Younossi, Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274–285 (2011).
Patton, H. M. et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 135, 1961–1971. e2 (2008).
Molleston, J. P. et al. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J. Pediatr. 164, 707–713. e3 (2014).
Saadeh, S. & Younossi, Z. M. The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic steatohepatitis. Cleve. Clin. J. Med. 67, 96–97, 101–104 (2000).
Fishbein, M. et al. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J. Clin. Gastroenterol. 39, 619–625 (2005).
Pacifico, L. et al. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr. 96, 542–547 (2007).
Loomba, R. et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61, 1239–1250 (2015).
Rorat, M. et al. Liver steatosis in Polish children assessed by medicolegal autopsies. World J. Pediatr. 9, 68–72 (2013).
Yüksel, F. et al. Fatty liver disease in an autopsy series of children and adolescents. Hippokratia 16, 61–65 (2012).
Wiegand, S. et al. Obese boys at increased risk for nonalcoholic liver disease: evaluation of 16, 390 overweight or obese children and adolescents. Int. J. Obes. (Lond.) 34, 1468–1474 (2010).
Boyraz, M. et al. Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria. Obes. Res. Clin. Pract. 8, e356–e363 (2014).
Lin, Y. C., Chang, P. F., Yeh, S. J., Liu, K. & Chen, H. C. Risk factors for liver steatosis in obese children and adolescents. Pediatr. Neonatol. 51, 149–154 (2010).
Farrell, G. C., Wong, V. W. & Chitturi, S. NAFLD in Asia—as common and important as in the West. Nat. Rev. Gastroenterol. Hepatol. 10, 307–318 (2013).
Dassanayake, A. S. et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J. Gastroenterol. Hepatol. 24, 1284–1288 (2009).
Masarone, M., Federico, A., Abenavoli, L., Loguercio, C. & Persico, M. Nonalcoholic fatty liver: epidemiology and natural history. Rev. Recent Clin. Trials 9, 126–133 (2014).
Schwimmer, J. B., McGreal, N., Deutsch, R., Finegold, M. J. & Lavine, J. E. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 115, e561–e565 (2005).
Lazo, M. et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988–1994. Am. J. Epidemiol. 178, 38–45 (2013).
Browning, J. D. et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387–1395 (2004).
Clark, J. M., Brancati, F. L. & Diehl, A. M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 98, 960–967 (2003).
Yang, J. D. et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 59, 1406–1414 (2014).
Jungermann, K. & Kietzmann, T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 31, 255–260 (2000).
Yeh, M. M. & Brunt, E. M. Pathological features of fatty liver disease. Gastroenterology 147, 754–764 (2014).
Schwimmer, J. B. et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42, 641–649 (2005).
Carter-Kent, C. et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 50, 1113–1120 (2009).
Takahashi, Y., Inui, A., Fujisawa, T., Takikawa, H. & Fukusato, T. Histopathological characteristics of non-alcoholic fatty liver disease in children: comparison with adult cases. Hepatol. Res. 41, 1066–1074 (2011).
Ko, J. S. et al. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig. Dis. Sci. 54, 2225–2230 (2009).
Feldstein, A. E. et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 58, 1538–1544 (2009).
US National Library of Medicine. ClinicalTrials.gov [online], (2015).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2015).
Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547–1554 (2015).
Angulo, P. et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2015.04.043.
Adams, L. A., Sanderson, S., Lindor, K. D. & Angulo, P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 42, 132–138 (2005).
Ekstedt, M. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865–873 (2006).
Argo, C. K., Northup, P. G., Al-Osaimi, A. M. & Caldwell, S. H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51, 371–379 (2009).
Wong, V. W. et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59, 969–974 (2010).
McPherson, S. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol. 62, 1148–1155 (2015).
Singh, S. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 13, 643–654. e1–e9 (2015).
Alkhouri, N. et al. Liver transplantation for nonalcoholic steatohepatitis (NASH) in children and young adults: the true burden of pediatric nonalcoholic fatty liver disease [abstract Su1038]. Gastroenterology 148, S-1046 (2015).
Nobili, V. et al. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity? Pediatr. Obes. 9, e99–e102 (2014).
Charlton, M. R. et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141, 1249–1253 (2011).
Altekruse, S. F., McGlynn, K. A. & Reichman, M. E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27, 1485–1491 (2009).
Altekruse, S. F., Henley, S. J., Cucinelli, J. E. & McGlynn, K. A. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am. J. Gastroenterol. 109, 542–553 (2014).
Calle, E. E., Rodriguez, C., Walker-Thurmond, K. & Thun, M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N. Engl. J. Med. 348, 1625–1638 (2003).
Alexander, J., Torbenson, M., Wu, T. T. & Yeh, M. M. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J. Gastroenterol. Hepatol. 28, 848–854 (2013).
Yasui, K. et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 9, 428–433 (2011).
Dongiovanni, P., Romeo, S. & Valenti, L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J. Gastroenterol. 20, 12945–12955 (2014).
Jiang, C. M. et al. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World J. Gastroenterol. 20, 16464–16473 (2014).
Stepanova, M. et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig. Dis. Sci. 58, 3017–3023 (2013).
Rafiq, N. et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 7, 234–238 (2009).
Ong, J. P., Pitts, A. & Younossi, Z. M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol. 49, 608–612 (2008).
Caldwell, S. & Argo, C. The natural history of non-alcoholic fatty liver disease. Dig. Dis. 28, 162–168 (2010).
Must, A. et al. The disease burden associated with overweight and obesity. JAMA 282, 1523–1529 (1999).
Park, J., Morley, T. S., Kim, M., Clegg, D. J. & Scherer, P. E. Obesity and cancer—mechanisms underlying tumour progression and recurrence. Nat. Rev. Endocrinol. 10, 455–465 (2014).
Dunn, W. et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am. J. Gastroenterol. 103, 2263–2271 (2008).
Lonardo, A., Ballestri, S., Targher, G. & Loria, P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 9, 629–650 (2015).
Schwimmer, J. B. et al. Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. PLoS ONE 9, e112569 (2014).
Pacifico, L. et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr. Res. 63, 423–427 (2008).
Demirciog˘lu, F. et al. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 47, 68–75 (2008).
Schenk, S., Saberi, M. & Olefsky, J. M. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118, 2992–3002 (2008).
Polyzos, S. A., Kountouras, J., Zavos, C. & Tsiaousi, E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes. Metab. 12, 365–383 (2010).
Polyzos, S. A., Kountouras, J., Zavos, C. & Deretzi, G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J. Clin. Gastroenterol. 45, 50–54 (2011).
Amir, M. & Czaja, M. J. Autophagy in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5, 159–166 (2011).
Takaki, A., Kawai, D. & Yamamoto, K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int. J. Mol. Sci. 15, 7352–7379 (2014).
Lake, A. D. et al. The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease. Toxicol. Sci. 137, 26–35 (2014).
Gusdon, A. M., Song, K. X. & Qu, S. Nonalcoholic fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid. Med. Cell. Longev. 2014, 637027 (2014).
Tilg, H. The role of cytokines in non-alcoholic fatty liver disease. Dig. Dis. 28, 179–185 (2010).
Sundaram, S. S. et al. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. J. Pediatr. 164, 699–706. e1 (2014).
Norman, D. et al. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep 31, 121–126 (2008).
Türkay, C. et al. Influence of obstructive sleep apnea on fatty liver disease: role of chronic intermittent hypoxia. Respir. Care 57, 244–249 (2012).
Bataller, R. & Brenner, D. A. Liver fibrosis. J. Clin. Invest. 115, 209–218 (2005).
Yu, Y. H. et al. Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications. Obes. Rev. 16, 234–247 (2015).
Scarpace, P. J. & Zhang, Y. Leptin resistance: a prediposing factor for diet-induced obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R493–R500 (2009).
Drubach, L. A. et al. Pediatric brown adipose tissue: detection, epidemiology, and differences from adults. J. Pediatr. 159, 939–944 (2011).
Rockstroh, D. et al. Direct evidence of brown adipocytes in different fat depots in children. PLoS ONE 10, e0117841 (2015).
Whitaker, R. C., Wright, J. A., Pepe, M. S., Seidel, K. D. & Dietz, W. H. Predicting obesity in young adulthood from childhood and parental obesity. N. Engl. J. Med. 337, 869–873 (1997).
Nishino, M., Hayakawa, K., Nakamura, Y., Morimoto, T. & Mukaihara, S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am. J. Roentgenol. 180, 129–134 (2003).
Cole, L. K., Jacobs, R. L. & Vance, D. E. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 52, 1258–1265 (2010).
Lazo, M. et al. Association between endogenous sex hormones and liver fat in a multiethnic study of atherosclerosis. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2014.12.033.
Baranova, A., Tran, T. P., Birerdinc, A. & Younossi, Z. M. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 33, 801–814 (2011).
Ramezani-Binabaj, M., Motalebi, M., Karimi-Sari, H., Rezaee-Zavareh, M. S. & Alavian, S. M. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic fatty liver disease; a meta-analysis. Hepat. Mon. 14, e23235 (2014).
Palmer, B. F. & Clegg, D. J. The sexual dimorphism of obesity. Mol. Cell. Endocrinol. 402, 113–119 (2015).
Suzuki, A. et al. Association between puberty and features of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 10, 786–794 (2012).
Goel, A., Gupta, M. & Aggarwal, R. Gut microbiota and liver disease. J. Gastroenterol. Hepatol. 29, 1139–1148 (2014).
Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).
Le Roy, T. et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62, 1787–1794 (2013).
Zhu, L. et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57, 601–609 (2013).
Roh, Y. S. & Seki, E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J. Gastroenterol. Hepatol. 28 (Suppl. 1), 38–42 (2013).
Paolella, G. et al. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J. Gastroenterol. 20, 15518–15531 (2014).
Galvez, M. P., Pearl, M. & Yen, I. H. Childhood obesity and the built environment. Curr. Opin. Pediatr. 22, 202–207 (2010).
Lobstein, T. et al. Child and adolescent obesity: part of a bigger picture. Lancet 385, 2510–2520 (2015).
Galvez, M. P. et al. Associations between neighborhood resources and physical activity in inner-city minority children. Acad. Pediatr. 13, 20–26 (2013).
Moore, J. B., Gunn, P. J. & Fielding, B. A. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients 6, 5679–5703 (2014).
Abdelmalek, M. F. et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51, 1961–1971 (2010).
Stanhope, K. L. et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J. Clin. Invest. 119, 1322–1334 (2009).
Vos, M. B. & Lavine, J. E. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 57, 2525–2531 (2013).
Chung, M. et al. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am. J. Clin. Nutr. 100, 833–849 (2014).
Lang, I. A. et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 300, 1303–1310 (2008).
Trasande, L., Attina, T. M. & Blustein, J. Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents. JAMA 308, 1113–1121 (2012).
Schwimmer, J. B. et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 136, 1585–1592 (2009).
Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461–1465 (2008).
Sookoian, S. & Pirola, C. J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53, 1883–1894 (2011).
Valenti, L. et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51, 1209–1217 (2010).
Trépo, E. et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology 59, 2170–2177 (2014).
Liu, Y. L. et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J. Hepatol. 61, 75–81 (2014).
Romeo, S. et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J. Hepatol. 53, 335–338 (2010).
Santoro, N. et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 52, 1281–1290 (2010).
Rotman, Y. et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52, 894–903 (2010).
Trépo, E. et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J. Hepatol. 55, 906–912 (2011).
Trépo, E. et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 54, 60–69 (2011).
Stättermayer, A. F. et al. Hepatic steatosis in Wilson disease—role of copper and PNPLA3 mutations. J. Hepatol. 63, 156–163 (2015).
Speliotes, E. K. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 7, e1001324 (2011).
Chalasani, N. et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 139, 1567–1576 (2010).
Tan, H. L. et al. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. J. Gastroenterol. 49, 1056–1064 (2014).
Aravinthan, A. et al. Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. Cell Cycle 13, 1489–1494 (2014).
Al-Serri, A. et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J. Hepatol. 56, 448–454 (2012).
Wang, X., Liu, Z., Peng, Z. & Liu, W. The TM6SF2 rs58542926 T allele is significantly associated with nonalcoholic fatty liver disease in Chinese. J. Hepatol. 62, 1438–1439 (2015).
Liu, Y. L. et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 4309 (2014).
Kozlitina, J., Boerwinkle, E., Cohen, J. C. & Hobbs, H. H. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 53, 467–474 (2011).
Zarrinpar, A., Gupta, S., Maurya, M. R., Subramaniam, S. & Loomba, R. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut http://dx.doi.org/10.1136/gutjnl-2015-309456.
Barlow, S. E. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 120 (Suppl. 4), S164–S192 (2007).
Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005–2023 (2012).
Loomba, R. et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 60, 1920–1928 (2014).
Cui, J. et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment. Pharmacol. Ther. 41, 1271–1280 (2015).
Guo, S. S., Wu, W., Chumlea, W. C. & Roche, A. F. Predicting overweight and obesity in adulthood from body mass index values in childhood and adolescence. Am. J. Clin. Nutr. 76, 653–658 (2002).
Promrat, K. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51, 121–129 (2010).
Vilar-Gomez, E. et al. Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2015.04.005.
Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005).
Kistler, K. D. et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am. J. Gastroenterol. 106, 460–468 (2011).
Oh, S. et al. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. Hepatology 61, 1205–1215 (2015).
Dudekula, A., Rachakonda, V., Shaik, B. & Behari, J. Weight loss in nonalcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS ONE 9, e111808 (2014).
Nobili, V. et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 48, 119–128 (2008).
Grønbæk, H. et al. Effect of a 10-week weight-loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J. Pediatr. Gastroenterol. Nutr. 54, 223–228 (2012).
Lavine, J. E. et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305, 1659–1668 (2011).
Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).
Trauner, M., Claudel, T., Fickert, P., Moustafa, T. & Wagner, M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig. Dis. 28, 220–224 (2010).
Fang, S. et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21, 159–165 (2015).
Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956–965 (2015).
Sjöström, L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J. Intern. Med. 273, 219–234 (2013).
Mathurin, P. et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137, 532–540 (2009).
Caiazzo, R. et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann. Surg. 260, 893–898 (2014).
Loy, J. J. et al. Improvement in nonalcoholic fatty liver disease and metabolic syndrome in adolescents undergoing bariatric surgery. Surg. Obes. Relat. Dis. 11, 442–449 (2015).
Nobili, V. et al. Indications and limitations of bariatric intervention in severely obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN Hepatology Committee Position Statement. J. Pediatr. Gastroenterol. Nutr. 60, 550–561 (2015).
Huang, T. T. et al. Assessing overweight, obesity, diet, and physical activity in college students. J. Am. Coll. Health 52, 83–86 (2003).
Nanney, M. S. et al. Weight and weight-related behaviors among 2-year college students. J. Am. Coll. Health 63, 221–229 (2015).
Slutske, W. S. Alcohol use disorders among US college students and their non-college-attending peers. Arch. Gen. Psychiatry 62, 321–327 (2005).
Hiramine, Y. et al. Alcohol drinking patterns and the risk of fatty liver in Japanese men. J. Gastroenterol. 46, 519–528 (2011).
Dunn, W., Xu, R. & Schwimmer, J. B. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 47, 1947–1954 (2008).
Tarantino, G., Citro, V. & Finelli, C. Recreational drugs: a new health hazard for patients with concomitant chronic liver diseases. J. Gastrointestin. Liver Dis. 23, 79–84 (2014).
Bailey, J. A., Fleming, C. B., Henson, J. N., Catalano, R. F. & Haggerty, K. P. Sexual risk behavior 6 months post-high school: associations with college attendance, living with a parent, and prior risk behavior. J. Adolesc. Health 42, 573–579 (2008).
Lowry, R., Robin, L., Kann, L. & Galuska, D. A. Associations of body mass index with sexual risk-taking and injection drug use among US high school students. J. Obes. 2014, 816071 (2014).
American Academy of Pediatrics. et al. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics 128, 182–200 (2011).
Vajro, P., Ferrante, L., Lenta, S., Mandato, C. & Persico, M. Management of adults with paediatric-onset chronic liver disease: strategic issues for transition care. Dig. Liver Dis. 46, 295–301 (2014).
Schwartz, L. A., Tuchman, L. K., Hobbie, W. L. & Ginsberg, J. P. A social-ecological model of readiness for transition to adult-oriented care for adolescents and young adults with chronic health conditions. Child Care Health Dev. 37, 883–895 (2011).
Schwartz, L. A. et al. Stakeholder validation of a model of readiness for transition to adult care. JAMA Pediatr. 167, 939–946 (2013).
Acknowledgements
The authors would like to thank M. Salamao for providing the images of NAFLD used in this paper. A.A.M., R.L. and J.E.L. are supported by NIH U01DK61734.
Author information
Authors and Affiliations
Contributions
A.A.M. researched data for the article. All the authors substantially contributed to discussion of content, wrote the article, and reviewed/edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Mencin, A., Loomba, R. & Lavine, J. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 12, 617–628 (2015). https://doi.org/10.1038/nrgastro.2015.146
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2015.146
This article is cited by
-
Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH
Scientific Reports (2019)
-
In a pilot study, reduced fatty acid desaturase 1 function was associated with nonalcoholic fatty liver disease and response to treatment in children
Pediatric Research (2018)
-
Non-alcoholic fatty liver disease and its associations among adolescents in an urban, Sri Lankan community
BMC Gastroenterology (2017)